HealthCareMagic is now Ask A Doctor - 24x7 | https://www.askadoctor24x7.com

Dr. Salman Arif , M.B.B.S., Post Graduate Diploma, F.C.P.S
Oncologist
Lahore, Punjab, Pakistan   View Clinic 

Rating:
4.58 stars (210 ratings)
4 Users viewed this profile
Certified Expert Certified Expert
Certified Expert 19 Doctors agree with him
Certified Expert 19 answers voted Helpful
Certified Expert 210 Answered 0 premium & 210 public questions
Be the First one to like this doctor

Contact Details
 
City
Lahore
State
Punjab
Country
Pakistan

Professional Details
 
State Licence Number/NPI
41627-P
State/Board registered with
Pakistan Medical and Dental Council
Specialty
Oncologist
Years of experience
17
Patients seen per week
80 
Procedures done per week
20 
Specific Skills and Interests
Treatment of solid cancers with chemotherapy and radiation therapy.
Special interest in treatment of Breast cancer, Lung cancer and Lymphomas. 
Clinic Detail 1
 
Location
Oncology Department,
Combined Military Hospital,
Lahore, Punjab, Pakistan View Clinic  
Timing
8:00 AM to 3:00 PM; 7:00 PM to 9:00 PM
 

Education Details
 
Graduation
 
Year
2002 
Degree earned
M.B.B.S. 
Name of the university
National University of Sciences and Technology N.U.S.T / Army Medical College, Rawalpindi 
Residency / Post graduation
 
Year of post-graduation
2008
Degree earned
Post Graduate Diploma
University/Hospital/Institute
Armed Forces Post Graduate Medical Institute A.F.P.G.M.I 
Fellowship / Specialty Training
 
Year of fellowship
2012
Degree earned
F.C.P.S
University/Hospital/Institute
College of Physicians and Surgeons Pakistan CPSP 

Other Details
 
Honors/Awards
Clinical Research: Participated as investigator in the following Multi national clinical trials
1.     A randomized, double-blind, placebo controlled, multicentre, phase III study comparing GW572026 and letrozole versus letrozole in subjects with Estrogen / progesterone receptor-positive advanced or metastatic breast cancer. (EGF 30008)

2.     A phase III, multicenter, randomized,double-blind, active controlled, parallel group study of the safety and oral formulations of the neurokinin-1 receptor antagonist, casopitant (GW 679769) in combination with ondansetron and dexamethasone for the prevention of nausea and vomiting induced by moderately ematogenic chemotherapy. (NKV 102549)

3.     To assess patient profile and pattern of care in operable breast cancer patient with intermediate to high risk of recurrence treated with docetaxel (Taxotere®)-based adjuvant chemotherapy (APBI)
 
Affiliations
Pakistan Society of Clinical Oncology P.S.C.O 
Other professional achievements
Publications:

Research Papers:     

1     Study of efficacy and toxicity of hypofractionated thoracic radiotherapy 17 Gray in 2 fractions for palliation in advanced non-small cell lung cancer at Combined Military Hospital Rawalpindi
     Pak Armed Forces Med J Dec 2012;3

2     Association of age with steroid receptor and HER-2/neu receptor status in breast cancer patients at Combined Military Hospital Rawalpindi
     Pak Armed Forces Med J Jun 2012;2

3     Frequency and severity of neutropenia in diffuse large B-cell non hodgkin's lymphoma after first cycle of chemotherapy comprising cyclophosphamide, doxorubicin, vincristine with prednisolon.
J Ayub Med Coll Abottabad Jan - Mar 2011;23(1):80-3.

4     Role of honey in prevention of radiation induced mucositis in head and neck cancer. Accepted for publication in Pak Armed Forces Med J 20th Mar 2013


5     Therapeutic effects of whole brain radiotherapy with carboplatin as radiation sensitizer in management of brain metastasis.
Pak Armed Forces Med J June 2013; 63(2): 249-53

Dissertations:

Study of efficacy and toxicity of hypofractionated thoracic radiotherapy 17 Gray in 2 fractions for palliation in advanced non-small cell lung cancer at Combined Military Hospital Rawalpindi. (Accepted by CPSP for FCPS)


Papers Presented:

1.     Hypofractionated thoracic Radiotherapy for palliation in advanced NSCLC. Oral Presentation at ONCO 2014

2.     Association of age with steroid receptor and Her 2 neu receptor status in breast cancer. Poster presentation at ONCO 2014